JP2010505930A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010505930A5 JP2010505930A5 JP2009531915A JP2009531915A JP2010505930A5 JP 2010505930 A5 JP2010505930 A5 JP 2010505930A5 JP 2009531915 A JP2009531915 A JP 2009531915A JP 2009531915 A JP2009531915 A JP 2009531915A JP 2010505930 A5 JP2010505930 A5 JP 2010505930A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- formula
- pain
- acid addition
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 178
- 150000003839 salts Chemical class 0.000 claims description 80
- 239000002253 acid Substances 0.000 claims description 76
- 238000000034 method Methods 0.000 claims description 69
- 208000002193 Pain Diseases 0.000 claims description 36
- 239000002246 antineoplastic agent Substances 0.000 claims description 28
- 102100034051 Heat shock protein HSP 90-alpha Human genes 0.000 claims description 24
- 101001016865 Homo sapiens Heat shock protein HSP 90-alpha Proteins 0.000 claims description 24
- 238000004519 manufacturing process Methods 0.000 claims description 23
- 239000003814 drug Substances 0.000 claims description 22
- 208000024891 symptom Diseases 0.000 claims description 22
- 238000011282 treatment Methods 0.000 claims description 22
- 241000124008 Mammalia Species 0.000 claims description 20
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 17
- 201000010099 disease Diseases 0.000 claims description 16
- 230000002265 prevention Effects 0.000 claims description 16
- 125000006239 protecting group Chemical group 0.000 claims description 16
- 125000000217 alkyl group Chemical group 0.000 claims description 12
- 239000012458 free base Substances 0.000 claims description 12
- 239000003429 antifungal agent Substances 0.000 claims description 11
- 229940121375 antifungal agent Drugs 0.000 claims description 11
- 208000006011 Stroke Diseases 0.000 claims description 10
- 229940041181 antineoplastic drug Drugs 0.000 claims description 10
- 230000002401 inhibitory effect Effects 0.000 claims description 10
- 230000001404 mediated effect Effects 0.000 claims description 10
- 230000002159 abnormal effect Effects 0.000 claims description 9
- 238000005984 hydrogenation reaction Methods 0.000 claims description 9
- 230000001575 pathological effect Effects 0.000 claims description 9
- 208000004454 Hyperalgesia Diseases 0.000 claims description 8
- 201000001320 Atherosclerosis Diseases 0.000 claims description 7
- 239000003054 catalyst Substances 0.000 claims description 7
- 230000000694 effects Effects 0.000 claims description 7
- 125000006645 (C3-C4) cycloalkyl group Chemical group 0.000 claims description 6
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 claims description 6
- 125000003342 alkenyl group Chemical group 0.000 claims description 6
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 claims description 6
- 238000009903 catalytic hydrogenation reaction Methods 0.000 claims description 6
- 239000003153 chemical reaction reagent Substances 0.000 claims description 6
- 229910052736 halogen Inorganic materials 0.000 claims description 6
- 150000002367 halogens Chemical class 0.000 claims description 6
- 229910052739 hydrogen Inorganic materials 0.000 claims description 6
- 239000001257 hydrogen Substances 0.000 claims description 6
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 6
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 claims description 6
- 230000002441 reversible effect Effects 0.000 claims description 6
- 229940124597 therapeutic agent Drugs 0.000 claims description 6
- 241001465754 Metazoa Species 0.000 claims description 5
- 206010028980 Neoplasm Diseases 0.000 claims description 5
- 239000003096 antiparasitic agent Substances 0.000 claims description 5
- 229940125687 antiparasitic agent Drugs 0.000 claims description 5
- 239000003904 antiprotozoal agent Substances 0.000 claims description 5
- 230000000903 blocking effect Effects 0.000 claims description 5
- 201000011510 cancer Diseases 0.000 claims description 5
- 230000004663 cell proliferation Effects 0.000 claims description 5
- 229910052723 transition metal Inorganic materials 0.000 claims description 5
- 150000003624 transition metals Chemical class 0.000 claims description 5
- 230000029812 viral genome replication Effects 0.000 claims description 5
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 claims description 4
- 206010003658 Atrial Fibrillation Diseases 0.000 claims description 4
- 206010058019 Cancer Pain Diseases 0.000 claims description 4
- 208000000094 Chronic Pain Diseases 0.000 claims description 4
- 206010059866 Drug resistance Diseases 0.000 claims description 4
- 208000005171 Dysmenorrhea Diseases 0.000 claims description 4
- 206010019233 Headaches Diseases 0.000 claims description 4
- 208000035154 Hyperesthesia Diseases 0.000 claims description 4
- 208000031226 Hyperlipidaemia Diseases 0.000 claims description 4
- 206010020751 Hypersensitivity Diseases 0.000 claims description 4
- 206010065390 Inflammatory pain Diseases 0.000 claims description 4
- JVTAAEKCZFNVCJ-REOHCLBHSA-N L-lactic acid Chemical compound C[C@H](O)C(O)=O JVTAAEKCZFNVCJ-REOHCLBHSA-N 0.000 claims description 4
- 206010028391 Musculoskeletal Pain Diseases 0.000 claims description 4
- 208000001294 Nociceptive Pain Diseases 0.000 claims description 4
- 208000004550 Postoperative Pain Diseases 0.000 claims description 4
- 208000025747 Rheumatic disease Diseases 0.000 claims description 4
- 208000035868 Vascular inflammations Diseases 0.000 claims description 4
- 206010047095 Vascular pain Diseases 0.000 claims description 4
- 208000036142 Viral infection Diseases 0.000 claims description 4
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 claims description 4
- 239000012346 acetyl chloride Substances 0.000 claims description 4
- 208000005298 acute pain Diseases 0.000 claims description 4
- 208000026935 allergic disease Diseases 0.000 claims description 4
- 206010053552 allodynia Diseases 0.000 claims description 4
- 208000037849 arterial hypertension Diseases 0.000 claims description 4
- 206010012601 diabetes mellitus Diseases 0.000 claims description 4
- 231100000869 headache Toxicity 0.000 claims description 4
- 230000009610 hypersensitivity Effects 0.000 claims description 4
- 208000015181 infectious disease Diseases 0.000 claims description 4
- 230000002458 infectious effect Effects 0.000 claims description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 4
- 230000003211 malignant effect Effects 0.000 claims description 4
- 230000000926 neurological effect Effects 0.000 claims description 4
- 230000009467 reduction Effects 0.000 claims description 4
- 238000006722 reduction reaction Methods 0.000 claims description 4
- 230000000552 rheumatic effect Effects 0.000 claims description 4
- 208000004371 toothache Diseases 0.000 claims description 4
- 230000009385 viral infection Effects 0.000 claims description 4
- 230000003612 virological effect Effects 0.000 claims description 4
- 208000009935 visceral pain Diseases 0.000 claims description 4
- 241000223960 Plasmodium falciparum Species 0.000 claims description 3
- 230000005875 antibody response Effects 0.000 claims description 3
- 230000002538 fungal effect Effects 0.000 claims description 3
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 3
- 230000003071 parasitic effect Effects 0.000 claims description 3
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 2
- YZUPZGFPHUVJKC-UHFFFAOYSA-N 1-bromo-2-methoxyethane Chemical compound COCCBr YZUPZGFPHUVJKC-UHFFFAOYSA-N 0.000 claims description 2
- 208000028389 Nerve injury Diseases 0.000 claims description 2
- 239000003729 cation exchange resin Substances 0.000 claims description 2
- 230000002708 enhancing effect Effects 0.000 claims description 2
- 238000010438 heat treatment Methods 0.000 claims description 2
- 125000005842 heteroatom Chemical group 0.000 claims description 2
- 125000000623 heterocyclic group Chemical group 0.000 claims description 2
- 239000003112 inhibitor Substances 0.000 claims description 2
- 239000004310 lactic acid Substances 0.000 claims description 2
- 235000014655 lactic acid Nutrition 0.000 claims description 2
- 125000005905 mesyloxy group Chemical group 0.000 claims description 2
- 230000008764 nerve damage Effects 0.000 claims description 2
- 229910052757 nitrogen Inorganic materials 0.000 claims description 2
- 229910052760 oxygen Inorganic materials 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 claims description 2
- 230000008569 process Effects 0.000 claims description 2
- 238000006268 reductive amination reaction Methods 0.000 claims description 2
- 239000011347 resin Substances 0.000 claims description 2
- 229920005989 resin Polymers 0.000 claims description 2
- -1 sodium triacetoxyborohydride Chemical compound 0.000 claims description 2
- 239000012321 sodium triacetoxyborohydride Substances 0.000 claims description 2
- 229910052717 sulfur Inorganic materials 0.000 claims description 2
- ITMCEJHCFYSIIV-UHFFFAOYSA-N triflic acid Chemical compound OS(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-N 0.000 claims description 2
- 201000009030 Carcinoma Diseases 0.000 claims 3
- 229940079593 drug Drugs 0.000 claims 2
- 208000019691 hematopoietic and lymphoid cell neoplasm Diseases 0.000 claims 2
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 208000004463 Follicular Adenocarcinoma Diseases 0.000 claims 1
- 208000022072 Gallbladder Neoplasms Diseases 0.000 claims 1
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 claims 1
- 208000007766 Kaposi sarcoma Diseases 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 201000010208 Seminoma Diseases 0.000 claims 1
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 206010043276 Teratoma Diseases 0.000 claims 1
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 201000006083 Xeroderma Pigmentosum Diseases 0.000 claims 1
- 230000001093 anti-cancer Effects 0.000 claims 1
- 210000001185 bone marrow Anatomy 0.000 claims 1
- 201000007455 central nervous system cancer Diseases 0.000 claims 1
- 208000025997 central nervous system neoplasm Diseases 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 208000035475 disorder Diseases 0.000 claims 1
- 210000002615 epidermis Anatomy 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 201000010175 gallbladder cancer Diseases 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 201000008806 mesenchymal cell neoplasm Diseases 0.000 claims 1
- 210000005036 nerve Anatomy 0.000 claims 1
- 230000000324 neuroprotective effect Effects 0.000 claims 1
- 201000008968 osteosarcoma Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 201000005528 peripheral nervous system neoplasm Diseases 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 230000002062 proliferating effect Effects 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 201000002510 thyroid cancer Diseases 0.000 claims 1
- 210000001685 thyroid gland Anatomy 0.000 claims 1
- 208000030901 thyroid gland follicular carcinoma Diseases 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- 0 CC(C)c(cc(C(N(C1)Cc2c1ccc(CN1CCN(*)CC1)c2)=O)c(O)c1)c1O Chemical compound CC(C)c(cc(C(N(C1)Cc2c1ccc(CN1CCN(*)CC1)c2)=O)c(O)c1)c1O 0.000 description 21
- 239000013078 crystal Chemical group 0.000 description 12
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 4
- 230000010261 cell growth Effects 0.000 description 4
- 208000006168 Ewing Sarcoma Diseases 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- 206010025135 lupus erythematosus Diseases 0.000 description 3
- 238000011321 prophylaxis Methods 0.000 description 3
- PBWGTOOLBHCMNP-UHFFFAOYSA-N CC(C)c(cc(C(N(C1)Cc2c1ccc(CNCCNC)c2)=O)c(O)c1)c1O Chemical compound CC(C)c(cc(C(N(C1)Cc2c1ccc(CNCCNC)c2)=O)c(O)c1)c1O PBWGTOOLBHCMNP-UHFFFAOYSA-N 0.000 description 2
- KERQOIXKIUJGQE-UHFFFAOYSA-N CC(c(c(OCc1ccccc1)c1)cc(C(OC)=O)c1OCc1ccccc1)=C Chemical compound CC(c(c(OCc1ccccc1)c1)cc(C(OC)=O)c1OCc1ccccc1)=C KERQOIXKIUJGQE-UHFFFAOYSA-N 0.000 description 2
- RDWLGPMLGHAUIC-UHFFFAOYSA-N CC(c(c(OCc1ccccc1)c1)cc(C(OC)=O)c1OCc1ccccc1)=O Chemical compound CC(c(c(OCc1ccccc1)c1)cc(C(OC)=O)c1OCc1ccccc1)=O RDWLGPMLGHAUIC-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 125000000555 isopropenyl group Chemical group [H]\C([H])=C(\*)C([H])([H])[H] 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 229910052763 palladium Inorganic materials 0.000 description 2
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 1
- FPIRBHDGWMWJEP-UHFFFAOYSA-N 1-hydroxy-7-azabenzotriazole Chemical compound C1=CN=C2N(O)N=NC2=C1 FPIRBHDGWMWJEP-UHFFFAOYSA-N 0.000 description 1
- ALPBVTMNNRPKOJ-UHFFFAOYSA-N CC(c(c(O)c1)cc(C(OC)=O)c1O)=O Chemical compound CC(c(c(O)c1)cc(C(OC)=O)c1O)=O ALPBVTMNNRPKOJ-UHFFFAOYSA-N 0.000 description 1
- IIFCLXHRIYTHPV-UHFFFAOYSA-N COC(c(ccc(O)c1)c1O)=O Chemical compound COC(c(ccc(O)c1)c1O)=O IIFCLXHRIYTHPV-UHFFFAOYSA-N 0.000 description 1
- 150000001204 N-oxides Chemical class 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 150000001718 carbodiimides Chemical class 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000033077 cellular process Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
- UKVIEHSSVKSQBA-UHFFFAOYSA-N methane;palladium Chemical group C.[Pd] UKVIEHSSVKSQBA-UHFFFAOYSA-N 0.000 description 1
- 238000002715 modification method Methods 0.000 description 1
- 230000004112 neuroprotection Effects 0.000 description 1
- 239000012038 nucleophile Substances 0.000 description 1
- QBERHIJABFXGRZ-UHFFFAOYSA-M rhodium;triphenylphosphane;chloride Chemical group [Cl-].[Rh].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 QBERHIJABFXGRZ-UHFFFAOYSA-M 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000011995 wilkinson's catalyst Substances 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US82924306P | 2006-10-12 | 2006-10-12 | |
| US60/829.243 | 2006-10-12 | ||
| GB0620259.2 | 2006-10-12 | ||
| GBGB0620259.2A GB0620259D0 (en) | 2006-10-12 | 2006-10-12 | Pharmaceutical compounds |
| PCT/GB2007/003871 WO2008044034A1 (en) | 2006-10-12 | 2007-10-12 | Hydrobenzamide derivatives as inhibitors of hsp90 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010505930A JP2010505930A (ja) | 2010-02-25 |
| JP2010505930A5 true JP2010505930A5 (https=) | 2011-12-22 |
| JP5726416B2 JP5726416B2 (ja) | 2015-06-03 |
Family
ID=37491396
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009531915A Active JP5726416B2 (ja) | 2006-10-12 | 2007-10-12 | Ｈｓｐ９０の阻害剤としてのヒドロベンズアミド誘導体 |
Country Status (28)
| Country | Link |
|---|---|
| US (2) | US8653084B2 (https=) |
| EP (2) | EP2081895B1 (https=) |
| JP (1) | JP5726416B2 (https=) |
| KR (1) | KR101571568B1 (https=) |
| CN (1) | CN101848892B (https=) |
| AU (1) | AU2007306104B2 (https=) |
| BR (1) | BRPI0719879A8 (https=) |
| CA (1) | CA2665931C (https=) |
| CY (2) | CY1113873T1 (https=) |
| DK (2) | DK2546233T3 (https=) |
| ES (2) | ES2662359T3 (https=) |
| GB (1) | GB0620259D0 (https=) |
| HR (2) | HRP20130255T1 (https=) |
| HU (1) | HUE037268T2 (https=) |
| IL (1) | IL197934A (https=) |
| LT (1) | LT2546233T (https=) |
| ME (1) | ME01874B (https=) |
| MX (1) | MX2009003739A (https=) |
| NO (1) | NO342242B1 (https=) |
| NZ (1) | NZ576110A (https=) |
| PL (2) | PL2081895T3 (https=) |
| PT (2) | PT2081895E (https=) |
| RS (2) | RS52716B (https=) |
| RU (1) | RU2490258C2 (https=) |
| SI (2) | SI2546233T1 (https=) |
| TW (1) | TWI429638B (https=) |
| WO (1) | WO2008044034A1 (https=) |
| ZA (1) | ZA200902270B (https=) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101411167B1 (ko) | 2005-04-13 | 2014-06-23 | 아스텍스 테라퓨틱스 리미티드 | 하이드록시벤즈아미드 유도체 및 ｈｓｐ90 억제제로서의이의 용도 |
| US7754725B2 (en) | 2006-03-01 | 2010-07-13 | Astex Therapeutics Ltd. | Dihydroxyphenyl isoindolymethanones |
| JP5410285B2 (ja) * | 2006-10-12 | 2014-02-05 | アステックス、セラピューティックス、リミテッド | 医薬化合物 |
| GB0620259D0 (en) | 2006-10-12 | 2006-11-22 | Astex Therapeutics Ltd | Pharmaceutical compounds |
| WO2008044041A1 (en) | 2006-10-12 | 2008-04-17 | Astex Therapeutics Limited | Pharmaceutical combinations |
| JP5518478B2 (ja) | 2006-10-12 | 2014-06-11 | アステックス、セラピューティックス、リミテッド | 医薬化合物 |
| JP5528807B2 (ja) * | 2006-10-12 | 2014-06-25 | アステックス、セラピューティックス、リミテッド | 複合薬剤 |
| GB0806527D0 (en) | 2008-04-11 | 2008-05-14 | Astex Therapeutics Ltd | Pharmaceutical compounds |
| US9096518B2 (en) | 2009-06-22 | 2015-08-04 | Millennium Pharmaceuticals, Inc. | Substituted hydroxamic acids and uses thereof |
| AR077405A1 (es) | 2009-07-10 | 2011-08-24 | Sanofi Aventis | Derivados del indol inhibidores de hsp90, composiciones que los contienen y utilizacion de los mismos para el tratamiento del cancer |
| FR2949467B1 (fr) | 2009-09-03 | 2011-11-25 | Sanofi Aventis | Nouveaux derives de 5,6,7,8-tetrahydroindolizine inhibiteurs d'hsp90, compositions les contenant et utilisation |
| GB201009853D0 (en) | 2010-06-11 | 2010-07-21 | Chroma Therapeutics Ltd | HSP90 inhibitors |
| SMT201900660T1 (it) * | 2012-02-09 | 2020-01-14 | Univ Kansas | Inibitori c-terminali di hsp90 |
| MX2014014188A (es) * | 2012-05-25 | 2015-05-11 | Berg Llc | Metodos para tratar un sindrome metaboilico mediante la modulacion de la proteina de choque termico (hsp) 90-beta. |
| WO2015140624A1 (en) | 2014-03-20 | 2015-09-24 | Otsuka Pharmaceutical Co., Ltd. | Pharmaceutical formulation comprising a substitued phenyl- (1, 3-dihydro-isoindol-2-yl) -methanone |
| US10023864B2 (en) | 2014-06-06 | 2018-07-17 | Berg Llc | Methods of treating a metabolic syndrome by modulating heat shock protein (HSP) 90-beta |
| CN115397811B (zh) * | 2020-01-20 | 2025-05-23 | 奈奥芬莱有限公司 | 与atp结合位点结合的异吲哚啉衍生物 |
| GB202008201D0 (en) | 2020-06-01 | 2020-07-15 | Neophore Ltd | Inhibitor compounds |
| CN114767683A (zh) * | 2022-04-29 | 2022-07-22 | 暨南大学 | Onalespib在制备预防和/或治疗腺病毒感染的药物中的应用 |
| CN117700350A (zh) * | 2023-03-31 | 2024-03-15 | 福建医科大学 | 一种靶向降解hsp90蛋白的化合物及其制备方法与应用 |
Family Cites Families (103)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5540563Y2 (https=) | 1972-04-26 | 1980-09-22 | ||
| JPS4910506A (https=) | 1972-05-31 | 1974-01-30 | ||
| US4582909A (en) * | 1984-02-02 | 1986-04-15 | Warner-Lambert Company | Benzobicyclic lactam acids and derivatives as cognition activators |
| US4666828A (en) | 1984-08-15 | 1987-05-19 | The General Hospital Corporation | Test for Huntington's disease |
| US4760064A (en) * | 1984-12-18 | 1988-07-26 | Otsuka Pharmaceutical Co., Ltd. | Carbostyril compounds, compositions containing same and processes for preparing same |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4801531A (en) | 1985-04-17 | 1989-01-31 | Biotechnology Research Partners, Ltd. | Apo AI/CIII genomic polymorphisms predictive of atherosclerosis |
| KR0143565B1 (ko) | 1988-06-13 | 1998-07-15 | 사노 가즈오 | 피발산의 p-치환된 페닐 에스테르 유도체, 그의 제조 방법 및 이를 포함하는 조성물. |
| US4990511A (en) | 1988-08-03 | 1991-02-05 | Takeda Chemical Industries, Ltd. | Amide compounds, their production and use |
| US5272057A (en) | 1988-10-14 | 1993-12-21 | Georgetown University | Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase |
| US5192659A (en) | 1989-08-25 | 1993-03-09 | Genetype Ag | Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes |
| GB8926560D0 (en) | 1989-11-24 | 1990-01-17 | Zambeletti Spa L | Pharmaceuticals |
| US5124350A (en) * | 1990-06-28 | 1992-06-23 | G. D. Searle & Co. | Leukotriene b4 antagonists |
| ZA916555B (en) | 1990-08-27 | 1993-04-28 | Lilly Co Eli | Method of treating inflammatory bowel disease |
| FR2669029B1 (fr) * | 1990-11-14 | 1994-09-02 | Adir | Nouveaux derives de la n-benzoyl proline, leur procede de preparation et les compositions pharmaceutiques qui les contiennent. |
| US5280046A (en) | 1991-02-22 | 1994-01-18 | The University Of Colorado Foundation, Inc. | Method of treating type I diabetes |
| WO1992017467A1 (en) | 1991-04-06 | 1992-10-15 | Dr Lo. Zambeletti S.P.A. | Substituted azacyclic compounds, process for their preparation and their use as analgesics |
| US5619092A (en) * | 1993-02-01 | 1997-04-08 | Motorola | Enhanced electron emitter |
| US5633283A (en) | 1995-01-23 | 1997-05-27 | Eli Lilly And Company | Method for treating multiple sclerosis |
| JPH0910506A (ja) | 1995-06-30 | 1997-01-14 | Toshiba Corp | 脱気器 |
| WO1998004689A1 (en) | 1995-07-31 | 1998-02-05 | Urocor, Inc. | Biomarkers and targets for diagnosis, prognosis and management of prostate disease |
| US6218529B1 (en) | 1995-07-31 | 2001-04-17 | Urocor, Inc. | Biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer |
| JP3855026B2 (ja) | 1996-01-16 | 2006-12-06 | 富士レビオ株式会社 | アミド誘導体の製造方法 |
| WO1997026884A1 (en) | 1996-01-29 | 1997-07-31 | The Regents Of The University Of California | Method for treating sexual dysfunctions |
| GB9606187D0 (en) | 1996-03-23 | 1996-05-29 | Inst Of Food Research | Production of vanillin |
| JP2000507955A (ja) | 1996-04-03 | 2000-06-27 | メルク エンド カンパニー インコーポレーテッド | ファルネシル―タンパク質転移酵素の阻害剤 |
| AU714477B2 (en) | 1996-04-19 | 2000-01-06 | Regents Of The University Of California, The | Treatment of mood/affective disorders by glutamatergic upmodulators |
| IL118657A0 (en) | 1996-06-14 | 1996-10-16 | Arad Dorit | Inhibitors for picornavirus proteases |
| JP2001514631A (ja) | 1997-03-07 | 2001-09-11 | ノボ ノルディスク アクティーゼルスカブ | ４，５，６，７−テトラヒドロ−チエノ［３，２−ｃ］ピリジン誘導体類、それらの製造方法及び使用 |
| UY24949A1 (es) | 1997-04-08 | 2001-04-30 | Smithkline Beecham Corp | Compuestos calcilíticos |
| US6159979A (en) | 1997-04-18 | 2000-12-12 | Smithkline Beecham P.L.C. | Bicyclic aryl or a bicyclic heterocyclic ring containing compounds having a combined 5HT1A, 5HT1B and 5HT1D receptor antagonistic activity |
| US6329368B1 (en) | 1997-05-09 | 2001-12-11 | The Regents Of The University Of California | Endocrine modulation with positive modulators of AMPA type glutamate receptors |
| ATE317226T1 (de) | 1997-10-27 | 2006-02-15 | Cortex Pharma Inc | Behandlung der schizophrenie mit ampakinen und neuroleptika |
| AU1804299A (en) | 1997-12-08 | 1999-06-28 | Glycomed Incorporated | Sialyl lewis x and sialyl lewis a glycomimetics |
| EP1165492A1 (en) | 1999-03-30 | 2002-01-02 | Pharmacor Inc. | Hydroxyphenyl derivatives with hiv integrase inhibitory properties |
| DE19955283A1 (de) | 1999-11-17 | 2001-05-23 | Aventis Res & Tech Gmbh & Co | Verfahren zur enantioselektiven Gewinnung von Aminosäuren und Aminosäurederivaten unter Verwendung von Racemisierungskatalysatoren |
| WO2001036351A2 (en) | 1999-11-19 | 2001-05-25 | Corvas International, Inc. | Plasminogen activator inhibitor antagonists related applications |
| AU2001243158A1 (en) | 2000-02-18 | 2001-08-27 | Merck And Co., Inc. | Inhibitors of prenyl-protein transferase |
| GB0008305D0 (en) * | 2000-04-06 | 2000-05-24 | Neutec Pharma Plc | Treatment of fungal infections |
| DE60115227T2 (de) * | 2000-05-11 | 2006-08-24 | Bristol-Myers Squibb Co. | Tetrahydroisochinolin-analoga als wachstumshormon-sekretagoga |
| US7229986B2 (en) * | 2000-05-16 | 2007-06-12 | Takeda Pharmaceutical Company Ltd. | Melanin-concentrating hormone antagonist |
| DE10024939A1 (de) * | 2000-05-19 | 2001-11-29 | Bayer Ag | Neue Diphenylmethanderivate für Arzneimittel |
| CA2308994A1 (en) | 2000-05-19 | 2001-11-19 | Aegera Therapeutics Inc. | Neuroprotective compounds |
| FR2812876B1 (fr) * | 2000-08-08 | 2002-09-27 | Galderma Res & Dev | Nouveaux composes bi-aromatiques activateurs des recepteurs de type ppar-gamma et leur utilisation dans des compositions cosmetiques ou pharmaceutiques |
| KR20030059115A (ko) | 2000-08-25 | 2003-07-07 | 워너-램버트 캄파니 엘엘씨 | Ｎ-아릴-안트라닐산 및 그의 유도체의 제조 방법 |
| KR20090090406A (ko) * | 2000-12-18 | 2009-08-25 | 가부시키가이샤 이야쿠 분지 셋케이 겐쿠쇼 | 염증성 사이토카인 생산 유리 억제제 |
| AU2002366362A1 (en) | 2001-12-18 | 2003-06-30 | Bayer Aktiengesellschaft | 2-substituted pyrrolo(2.1-a)isoquinolines against cancer |
| CN1620294A (zh) | 2001-12-20 | 2005-05-25 | Osi药物公司 | 嘧啶a2b选择性拮抗剂化合物,它们的合成及用途 |
| EP1456180B1 (en) | 2001-12-21 | 2007-10-03 | Vernalis (Cambridge) Limited | 3-(2,4)dihydroxyphenyl-4-phenylpyrazoles and their medical use |
| JP2005537223A (ja) | 2002-04-05 | 2005-12-08 | ニトロメッド，インク． | 酸化窒素供与体、組成物および使用法 |
| EP1512396A4 (en) | 2002-06-05 | 2008-12-31 | Inst Med Molecular Design Inc | HEMMER AGAINST ACTIVATION OF AP-1 AND NFAT |
| WO2003103658A1 (ja) * | 2002-06-05 | 2003-12-18 | 株式会社医薬分子設計研究所 | 免疫関連プロテインキナーゼ阻害剤 |
| WO2003103648A1 (ja) * | 2002-06-05 | 2003-12-18 | 株式会社医薬分子設計研究所 | 糖尿病治療薬 |
| CA2488367A1 (en) | 2002-06-06 | 2003-12-18 | Institute Of Medicinal Molecular Design, Inc. | Antiallergic agents |
| SE0202133D0 (sv) | 2002-07-08 | 2002-07-08 | Astrazeneca Ab | Novel compounds |
| DE60326473D1 (en) | 2002-07-16 | 2009-04-16 | Amura Therapeutics Ltd | Pyrrolderivate als hemmstoffe von cystein proteasen |
| WO2004035571A1 (en) | 2002-10-15 | 2004-04-29 | Rigel Pharmaceuticals, Inc. | Substituted indoles and their use as hcv inhibitors |
| TWI228885B (en) | 2003-01-23 | 2005-03-01 | Mediatek Inc | Method for controlling a mobile communication device to enter a power-saving mode and to recover timing after the mobile communication device leaves the power-saving mode |
| EA009919B1 (ru) | 2003-02-11 | 2008-04-28 | Вернэлис (Кембридж) Лимитед | Соединения изоксазола |
| RU2324493C2 (ru) * | 2003-02-20 | 2008-05-20 | Юниверсити Оф Коннектикут Хелт Сентер | Способ применения композиций, содержащих белки теплового шока или альфа-2-макроглобулин, для лечения рака и инфекционных болезней |
| JP2006518368A (ja) | 2003-02-21 | 2006-08-10 | ファイザー・インク | プロテインキナーゼ阻害剤としてのｎ−ヘテロシクリル置換アミノチアゾール誘導体 |
| JP4787150B2 (ja) | 2003-03-06 | 2011-10-05 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | Ｊｎｋ阻害剤 |
| CA2523677A1 (en) | 2003-04-30 | 2004-11-11 | Novartis Ag | Aminopropanol derivatives as sphingosine-1-phosphate receptor modulators |
| AU2004251949B2 (en) | 2003-06-27 | 2009-05-07 | Kyowa Hakko Kirin Co., Ltd. | Hsp90 family protein inhibitors |
| GB0315111D0 (en) | 2003-06-27 | 2003-07-30 | Cancer Rec Tech Ltd | Substituted 5-membered ring compounds and their use |
| TWI312345B (en) * | 2003-06-30 | 2009-07-21 | Mitsubishi Tanabe Pharma Corp | Process of preparating 3-acylaminobenzofuran-2-carboxylic acid derivatives |
| RU2006104697A (ru) * | 2003-07-16 | 2006-06-27 | Инститьют Оф Медисинал Молекьюлар Дизайн. Инк. (Jp) | Лекарственное средство для лечения пигментации кожи |
| PL2256106T3 (pl) | 2003-07-22 | 2015-08-31 | Astex Therapeutics Ltd | Związki 3,4-pochodne 1h-pirazolu i ich zastosowanie jako kinazy zależne od cyklin (cdk) i modulatory kinazy syntazy glikogenu-3 (gsk-3) |
| DK1658263T3 (da) | 2003-07-24 | 2010-09-27 | Leo Pharma As | Aminobenzophenonforbindelser |
| CN1856490A (zh) | 2003-07-28 | 2006-11-01 | 詹森药业有限公司 | 苯并咪唑、苯并噻唑和苯并噁唑衍生物及其作为lta4h调节剂的应用 |
| DE10335584B4 (de) * | 2003-07-31 | 2006-06-29 | Philipps-Universität Marburg | Verfahren zur Herstellung zyklischer Moleküle |
| DE10335726A1 (de) * | 2003-08-05 | 2005-03-03 | Bayer Cropscience Gmbh | Verwendung von Hydroxyaromaten als Safener |
| WO2005016889A1 (en) | 2003-08-08 | 2005-02-24 | Virginia Commonwealth University | Compounds having antiestrogenic and tissue selective estrogenic properties |
| EP1670804A2 (en) | 2003-09-10 | 2006-06-21 | GPC Biotech AG | Heterobicyclic compounds as pharmaceutically active agents |
| HRP20130098T1 (hr) | 2003-10-14 | 2013-02-28 | F. Hoffmann - La Roche Ag | MAKROCIKLIÄŚKE KARBOKSILNE KISELINE I ACILSULFONAMIDNI SPOJEVI KAO INHIBITORI REPLIKACIJE HCV-a |
| JP2007513082A (ja) | 2003-11-10 | 2007-05-24 | シエーリング アクチエンゲゼルシャフト | Ｃｃｒ−５アンタゴニストとして有用なベンジルエーテルアミン化合物 |
| JPWO2005063222A1 (ja) | 2003-12-26 | 2007-07-19 | 協和醗酵工業株式会社 | Ｈｓｐ９０ファミリー蛋白質阻害剤 |
| US7351709B2 (en) * | 2004-06-09 | 2008-04-01 | Wyeth | Estrogen receptor ligands |
| EP1781654A1 (en) | 2004-07-27 | 2007-05-09 | SGX Pharmaceuticals, Inc. | Pyrrolo-pyridine kinase modulators |
| CA2577752A1 (en) | 2004-08-20 | 2006-03-02 | The Regents Of The University Of Michigan | Small molecule inhibitors of anti-apoptotic bcl-2 family members and the uses thereof |
| DE102004049078A1 (de) | 2004-10-08 | 2006-04-13 | Merck Patent Gmbh | Phenylpyrazole |
| US7208630B2 (en) | 2004-10-27 | 2007-04-24 | University Of Kansas | Heat shock protein 90 inhibitors |
| JPWO2006051808A1 (ja) * | 2004-11-09 | 2008-05-29 | 協和醗酵工業株式会社 | Ｈｓｐ９０ファミリー蛋白質阻害剤 |
| WO2006055760A1 (en) * | 2004-11-18 | 2006-05-26 | Synta Pharmaceuticals Corp. | Triazole compounds that modulate hsp90 activity |
| EP1833819A1 (en) | 2004-12-30 | 2007-09-19 | Astex Therapeutics Limited | Pyrazole compounds that modulate the activity of cdk, gsk and aurora kinases |
| AR054425A1 (es) | 2005-01-21 | 2007-06-27 | Astex Therapeutics Ltd | Sales de adicion de piperidin 4-il- amida de acido 4-(2,6-dicloro-benzoilamino) 1h-pirazol-3-carboxilico. |
| DE602006010665D1 (en) | 2005-02-07 | 2010-01-07 | Hoffmann La Roche | Heterocyclsche substituierte phenylmethanone als inhibitoren des glycintransporters 1 |
| US20060183902A1 (en) * | 2005-02-15 | 2006-08-17 | Baxter Ellen W | Dihydroindolyl methanones as alpha 1a/1d adrenoreceptor modulators for the treatment of benign prostatic hypertrophy and lower urinary tract symptoms |
| CN101123954B (zh) | 2005-02-21 | 2011-07-13 | 协和发酵麒麟株式会社 | 抗肿瘤剂 |
| KR101411167B1 (ko) * | 2005-04-13 | 2014-06-23 | 아스텍스 테라퓨틱스 리미티드 | 하이드록시벤즈아미드 유도체 및 ｈｓｐ90 억제제로서의이의 용도 |
| JP2008540395A (ja) | 2005-05-03 | 2008-11-20 | ファイザー・インク | アミドレソルシノール化合物 |
| DK2444079T3 (en) | 2005-05-17 | 2017-01-30 | Sarcode Bioscience Inc | Compositions and Methods for the Treatment of Eye Diseases |
| WO2007050124A1 (en) | 2005-05-19 | 2007-05-03 | Xenon Pharmaceuticals Inc. | Fused piperidine derivatives and their uses as therapeutic agents |
| US7425633B2 (en) * | 2005-08-26 | 2008-09-16 | National Health Research Institutes | Pyrrolidine compounds |
| EP1808634B1 (en) * | 2006-01-12 | 2008-10-29 | Ondal Holding GmbH | Fixture to mount a device |
| US7754725B2 (en) * | 2006-03-01 | 2010-07-13 | Astex Therapeutics Ltd. | Dihydroxyphenyl isoindolymethanones |
| WO2008044041A1 (en) | 2006-10-12 | 2008-04-17 | Astex Therapeutics Limited | Pharmaceutical combinations |
| JP5410285B2 (ja) * | 2006-10-12 | 2014-02-05 | アステックス、セラピューティックス、リミテッド | 医薬化合物 |
| GB0620259D0 (en) * | 2006-10-12 | 2006-11-22 | Astex Therapeutics Ltd | Pharmaceutical compounds |
| EP2073802A1 (en) * | 2006-10-12 | 2009-07-01 | Astex Therapeutics Limited | Pharmaceutical combinations |
| JP5528807B2 (ja) * | 2006-10-12 | 2014-06-25 | アステックス、セラピューティックス、リミテッド | 複合薬剤 |
| JP5518478B2 (ja) | 2006-10-12 | 2014-06-11 | アステックス、セラピューティックス、リミテッド | 医薬化合物 |
| WO2008053319A1 (en) | 2006-10-30 | 2008-05-08 | Pfizer Products Inc. | Amide resorcinol compounds |
-
2006
- 2006-10-12 GB GBGB0620259.2A patent/GB0620259D0/en not_active Ceased
-
2007
- 2007-10-11 TW TW096138174A patent/TWI429638B/zh not_active IP Right Cessation
- 2007-10-12 PL PL07824125T patent/PL2081895T3/pl unknown
- 2007-10-12 RS RS20130118A patent/RS52716B/sr unknown
- 2007-10-12 ME MEP-2013-34A patent/ME01874B/me unknown
- 2007-10-12 PL PL12187611T patent/PL2546233T3/pl unknown
- 2007-10-12 ES ES12187611.4T patent/ES2662359T3/es active Active
- 2007-10-12 PT PT78241254T patent/PT2081895E/pt unknown
- 2007-10-12 EP EP07824125A patent/EP2081895B1/en active Active
- 2007-10-12 SI SI200732010T patent/SI2546233T1/en unknown
- 2007-10-12 RU RU2009117589/04A patent/RU2490258C2/ru not_active IP Right Cessation
- 2007-10-12 BR BRPI0719879A patent/BRPI0719879A8/pt not_active Application Discontinuation
- 2007-10-12 EP EP12187611.4A patent/EP2546233B1/en active Active
- 2007-10-12 DK DK12187611.4T patent/DK2546233T3/en active
- 2007-10-12 JP JP2009531915A patent/JP5726416B2/ja active Active
- 2007-10-12 RS RS20180350A patent/RS57079B1/sr unknown
- 2007-10-12 CA CA2665931A patent/CA2665931C/en not_active Expired - Fee Related
- 2007-10-12 NZ NZ576110A patent/NZ576110A/en not_active IP Right Cessation
- 2007-10-12 WO PCT/GB2007/003871 patent/WO2008044034A1/en not_active Ceased
- 2007-10-12 DK DK07824125.4T patent/DK2081895T3/da active
- 2007-10-12 CN CN2007800455503A patent/CN101848892B/zh not_active Expired - Fee Related
- 2007-10-12 KR KR1020097009666A patent/KR101571568B1/ko not_active Expired - Fee Related
- 2007-10-12 LT LTEP12187611.4T patent/LT2546233T/lt unknown
- 2007-10-12 HR HRP20130255TT patent/HRP20130255T1/hr unknown
- 2007-10-12 AU AU2007306104A patent/AU2007306104B2/en not_active Ceased
- 2007-10-12 SI SI200731206T patent/SI2081895T1/sl unknown
- 2007-10-12 MX MX2009003739A patent/MX2009003739A/es active IP Right Grant
- 2007-10-12 HU HUE12187611A patent/HUE037268T2/hu unknown
- 2007-10-12 PT PT121876114T patent/PT2546233T/pt unknown
- 2007-10-12 ES ES07824125T patent/ES2402903T3/es active Active
- 2007-10-12 US US12/445,130 patent/US8653084B2/en not_active Expired - Fee Related
-
2009
- 2009-04-01 ZA ZA2009/02270A patent/ZA200902270B/en unknown
- 2009-04-05 IL IL197934A patent/IL197934A/en active IP Right Grant
- 2009-05-12 NO NO20091858A patent/NO342242B1/no not_active IP Right Cessation
-
2013
- 2013-04-03 CY CY20131100278T patent/CY1113873T1/el unknown
-
2014
- 2014-01-07 US US14/149,450 patent/US9428439B2/en not_active Expired - Fee Related
-
2018
- 2018-03-02 HR HRP20180375TT patent/HRP20180375T1/hr unknown
- 2018-03-19 CY CY20181100318T patent/CY1120081T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010505930A5 (https=) | ||
| RU2009117589A (ru) | ПРОИЗВОДНЫЕ ГИДРОБЕНЗАМИДА В КАЧЕСТВЕ ИНГИБИТОРОВ Hsp90 | |
| CN110582483B (zh) | 含邻氨基杂芳环炔基的化合物及其制备方法和用途 | |
| TWI481604B (zh) | Novel 5-fluorouracil derivatives | |
| EP3349761A1 (en) | Hepatitis b core protein modulators | |
| EA027476B1 (ru) | Применение n-(4-{[6,7-бис-(метилокси)хинолин-4-ил]окси}фенил)-n'-(4-фторфенил)циклопропан-1,1-дикарбоксамида для лечения кастрационно-резистентного рака простаты и остеобластических метастазов в кости | |
| JP6630364B2 (ja) | 水溶性プロドラッグ | |
| JP2003512454A (ja) | 悪性腫瘍治療薬 | |
| EP2615092B1 (en) | Heterocyclic amino berbamine derivatives, preparation method and use thereof | |
| WO2022083657A1 (zh) | 取代苯并或吡啶并嘧啶胺类抑制剂及其制备方法和应用 | |
| JP6940504B2 (ja) | 置換５，６−ジヒドロ−６−フェニルベンゾ［ｆ］イソキノリン−２−アミンを調製するための方法 | |
| JP2008538779A5 (https=) | ||
| CN119110795A (zh) | 用于治疗与lpa受体活性相关的病症的化合物和组合物 | |
| TW200813066A (en) | Novel compounds | |
| JP5701387B2 (ja) | ベルバミンのジカルボキシミド誘導体、その調製方法及び使用 | |
| TW201815793A (zh) | 一種咪唑並異吲哚類衍生物的遊離鹼的結晶形式及其製備方法 | |
| US10093609B2 (en) | TAK1 kinase inhibitors, compositions, and uses related thereto | |
| JP2024507822A (ja) | Ｎ－（（ｒ）－２，３－ジヒドロキシプロポキシ）－３，４－ジフルオロ－２－（２－フルオロ－４－ヨードフェニルアミノ）－ベンズアミドの本質的に純粋な形態ｉｖの組成物及びその使用 | |
| US10428008B2 (en) | Nitroalkene non steroidal anti-inflammatory drugs (NA-NSAIDs) and methods of treating inflammation related conditions | |
| WO2020177657A1 (zh) | 一类具有降解Btk活性的化合物 | |
| JP2023002841A (ja) | 高血圧症及び／又は線維症を処置するための組成物 | |
| EP4442684A1 (en) | A class of pyrimidine compounds, and preparation method therefor and use thereof | |
| JPWO2020169736A5 (https=) | ||
| JP2022522539A (ja) | キナーゼ阻害剤の多形体、このような化合物を含有する医薬組成物、調製方法、および適用 | |
| JP7611593B2 (ja) | Ｈｄａｃ分解剤 |